Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events
Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events
复制标题
DOI：
10.1056/nejm200106283442601
复制
发表时间：
2001-06-28
影响因子：
158.5
通讯作者：
Gotto, AM
中科院分区：
文献类型：
--
作者：
Ridker, PM;Rifai, N;Gotto, AM
背景：C反应蛋白水平升高，即使在没有高脂血症的情况下，也与冠状动脉事件的风险增加有关。他汀类药物可降低C反应蛋白水平，与其对血脂水平的影响无关。我们假设他汀类药物可以预防无明显高脂血症的C反应蛋白水平升高的患者的冠状动脉事件。方法：在一项为期5年的洛伐他汀一级预防急性冠状动脉事件的随机试验中，5742名参与者在基线水平和一年后测定C反应蛋白水平。结果：随着基线水平的增加，冠状动脉事件的发生率显著增加。洛伐他汀治疗后C反应蛋白水平下降14.8%(P
Background: Elevated levels of C-reactive protein, even in the absence of hyperlipidemia, are associated with an increased risk of coronary events. Statin therapy reduces the level of C-reactive protein independently of its effect on lipid levels. We hypothesized that statins might prevent coronary events in persons with elevated C-reactive protein levels who did not have overt hyperlipidemia.Methods: The level of C-reactive protein was measured at base line and after one year in 5742 participants in a five-year randomized trial of lovastatin for the primary prevention of acute coronary events.Results: The rates of coronary events increased significantly with increases in the base-line levels of C-reactive protein. Lovastatin therapy reduced the C-reactive protein level by 14.8 percent (P